CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin

Jaewon Hyung, Bumjun Kim, Changhoon Yoo, Kyo-pyo Kim, Jae Ho Jeong, Heung-Moon Chang, Baek-Yeol Ryoo

Cancer Research and Treatment. 2019;51(3):901-909. Published online 2018 October 4 DOI: https://doi.org/10.4143/crt.2018.326

Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin

Jaewon Hyung, Bumjun Kim, Changhoon Yoo, Kyo-pyo Kim, Jae Ho Jeong, Heung-Moon Chang, Baek-Yeol Ryoo

Cancer Research and Treatment. 2019;51(3):901-909

Link1

Link2 Link3

P-106Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin chemotherapy: retrospective analysis of 142 patients

H Engin

Annals of Oncology. 2018;29(suppl_5):

Link1

Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer

Kwonoh Park, Kyu-pyo Kim, Seongjoon Park, Heung-Moon Chang

Asia-Pacific Journal of Clinical Oncology. 2016;13(1):13-20

Link1 Link2 Link3

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

T.J. Eberlein

Yearbook of Surgery. 2011;2011:310-312

Link1 Link2

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

R.K. Pearson

Yearbook of Gastroenterology. 2010;2010:96-97

Link1 Link2

Gemcitabine plus Cisplatin versus Capecitabine plus Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Retrospective Cohort Study

Sang Myung Woo, Woo Jin Lee, Ji Hun Kim, Dong Hwan Kim, Sung-Sik Han, Sang-Jae Park, Tae Hyun Kim, Ju Hee Lee, Young Hwan Koh, Eun Kyung Hong

Chemotherapy. 2013;59(3):232-238

Link1 Link2

Practical Use of Gemcitabine and Cisplatin Combination Therapy as First-Line Treatment for Japanese Patients with Advanced Biliary Tract Cancer

Hisato Kawakami, Isamu Okamoto, Wataru Okamoto, Masayuki Takeda, Shinya Ueda, Toshihiro Kudo, Shin-ichi Nishina, Yasuhito Fujisaka, Masaki Miyazaki, Junji Tsurutani, Takayasu Kurata, Kazuhiko Nakagawa

Journal of Cancer Therapy. 2013;04(06):1068-1073

Link1 Link2 Link3

Cost-Effectiveness of Gemcitabine Plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan

I. Arakawa, S. Uemura, H. Murasawa, T. Inoue

Value in Health. 2013;16(7):A416

Link1 Link2

766PPrognostic factors in patients with advanced biliary tract cancer (BTC) who showed durable disease control with first-line gemcitabine plus cisplatin (GemCis)

J Hyung, C Yoo, K-P Kim, B J Kim, J H Jeong, H-M Chang, B-Y Ryoo

Annals of Oncology. 2018;29(suppl_8):

Link1

767PPredictive factors of outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy

Y Suzuki, M Kan, G Kimura, K Umemoto, K Watanabe, M Sasaki, H Takahashi, Y Hashimoto, H Imaoka, I Ohno, S Mitsunaga, M Ikeda

Annals of Oncology. 2018;29(suppl_8):

Link1

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.